ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2013

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Rebecca A Marsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.